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Literature Review Examining Continuous Subcutaneous Insulin Infusion and Effects on 
Hemoglobin A1c, Hypoglycemia, Hyperglycemia/Diabetic Ketoacidosis, and Quality of Life 
Chapter 1:  Introduction 
 Diabetes is a life altering disease that can affect children at any age.  If diabetes is not 
properly controlled, it can lead to severe health problems and even death.  An autoimmune 
response in the body that targets and destroys the beta cells in the pancreas is responsible for the 
development of Type I diabetes in children.  Since 1921 researchers have studied the disease 
process and to this point there are no answers why this occurs or how to prevent this disease 
from happening.  The end result of the autoimmune response for children diagnosed with 
diabetes is to replace their lack of insulin production either with multiple daily injections (MDI) 
with insulin or continuous subcutaneous insulin infusion (CSII) via insulin pump (Buttaro, 
Trybulski, Bailey, & Sandberg-Cook, 2008).   
 Diabetes can be defined as type I or type II diabetes. Type I diabetes requires at least two 
insulin injections.  Type II diabetes treatment can consist of either oral glucose lowering 
medications and/or insulin.  It is noted that the incidence of type I diabetes children continues to 
rise in the United States.  About one in every 400 children and adolescents has type I diabetes.  
The percentage of new cases for type I diabetes each year is 19.7 % per 100,000 for individuals 
younger than 10 years of age and 18.6 % per 100,000 for individuals older than 10 years of age 
according to the National Diabetes Statistics by the National Institutes of Health (2011).  The 
Center for Disease Control’s (CDC’s) National Diabetes Fact Sheet (2011) found that over 25 % 
of people younger than 20, which accounts for 215,000 individuals, are diagnosed annually, with 
either type I or type II diabetes.  SEARCH for Diabetes in Youth, is a national multi-center 
study, which was funded and reported by the CDC and National Institutes of Health (NIH) 
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(2011), attempts to understand more about diabetes among children and young adults in the 
United States.  SEARCH found that each year from 2002 to 2005, over 15,600 individuals 
younger than 20 years old, were diagnosed with type I diabetes.  The most prevalent ethnic group 
affected in children is the non-Hispanic white group with 24.8 % per 100,000 ("National 
Diabetes Fact Sheet, 2011," 2011).   In 2007, 186,300 school-aged children were diagnosed with 
diabetes.  Diabetes is considered one of the most common diseases for children in this age group 
(Overview of Diabetes in Children and Adolescents from the National Diabetes Education 
Program (NDEP), 2011).  
 Diabetes is also a major financial burden for the United States.  The total direct and 
indirect cost of taking care of people with diabetes is 174 billion dollars.  A diabetic can expect 
medical expenditures to be 2.3 times higher than those without diabetes ("National Diabetes Fact 
Sheet, 2011," 2011).  Diabetes is the leading cause of kidney failure, lower extremity non-
traumatic amputations, and new cases of blindness.  Diabetes is also a major risk factor for heart 
disease and stroke ("National Diabetes Fact Sheet, 2011," 2011).  Because of these complications 
it is not surprising that diabetes is the seventh leading cause of death in the United States (CDC, 
2011).  The Diabetes Control and Complication Trial (DCCT) (1993) from 1982 to 1993 
examined individuals with Type I diabetes.  Data obtained from the trial showed that improved 
blood glucose significantly reduces complications caused from poor control.  The question that 
will be explored in this literature review is:  Will children, who are less than 18 years of age, 
who are using CSII, for at least one year, have an improved HbA1c, decreased hypoglycemic 
episodes, hyperglycemic/diabetic ketoacidosis (DKA) episodes, and improved quality of life 
(QOL) over those children who use MDI.   
In review of the literature, several definitions were used.   
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Continuous subcutaneous insulin infusion (CSII), delivers insulin through a 
subcutaneous catheter into the individual via an insulin pump, which is controlled by the 
individual or care taker.  The catheter is changed every two to three days.   
Multiple daily injections (MDI) are when the individual gives insulin injections with a 
subcutaneous needle.  Individuals can be classified as mildly, moderately, or severely 
hypoglycemic.   
Mild to moderate hypoglycemia is a glucose level less than 70 milligrams per deciliter.  
The individual is able to recognize the symptoms of hypoglycemia and take the necessary 
treatment steps (Leiter, Yale, Chiasson, Harris, Kleinstiver, and Sauriol, 2005).  Severe 
hypoglycemia is a glucose reading less than 50 milligrams per deciliter and when the individual 
is unable to treat without the assistance from others.  Severe hypoglycemia is associated with 
seizure and/or loss of consciousness (Weinzimer, 2004).    
Diabetic ketoacidosis acidosis (DKA) is caused from hyperglycemia, which leads to 
acidosis, dehydration, and osmotic diuresis in the individual.  If DKA is severe enough the 
individual will need to be hospitalized for rehydration, intravenous infusion of insulin, and 
correction of the acid-base imbalance.  The range for a fasting blood glucose level is between 
110 to 126 milligrams per deciliter (Buttaro et al., 2008).   
Hemoglobin A1c (HbA1c) is obtained every three to six months and assists in defining 
the level of control of diabetes in the individual.  In the literature reviews a normal non-diabetic 
HbA1c is 5.6 % or less.  A diabetic has a HbA1c of 6.5 % or higher.  Higher HbA1c levels 
indicate poor control and indicated glucose levels that are above the 126mg/dl ("HbA1c: 
MedlinePlus Medical Encyclopedia," 2012).   
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Rapid-acting insulin has an average apparent half-life of 81 minutes and lasts about 
three to five hours. This insulin is taken five to 10 minutes prior to meals and starts acting in 
about 15 minutes.  Short-acting insulin should be given 30 to 60 minutes before a meal and the 
maximum effect occurs two and half to five hours later.  The duration is five to seven hours. 
Intermediate-acting insulin begins to lower glucose levels one to four hours after the injection, 
and its maximum effect can be seen between fours and 14 hours.  Glargine, also known as 
Lantus, is a 24 hour basal insulin.  This medication is usually given once a day and is used in 
combination with a short-acting insulin.  There are also no peak action times with this 
medication.   
Reduction/improvement of HbA1c means that the HbA1C is a lower number than what 
it was originally. Significantly lower HbA1c levels indicates improvement in daily glucose levels 
which correlates with better diabetic control and reduces the risk of complications that diabetes 
causes ("Patient Education," 2010). 
The theoretical framework for this capstone project is the Neuman’s System Model.  In 
this model the basic system/structure is not only the child, but the care givers and medical 
professionals as well.  The lines of resistance in the model are to protect the child.  The older 
children can be protected by the care giver and medical professionals.  This can be accomplished 
by providing necessary education and guidance.  The younger children are protected by having 
the care givers and medical professionals assist in administration of insulin, strict glucose 
control, and meal preparation.  Examples of lines of resistance can be education that is provided 
about CSII in clinical trial from medical professionals, constant contact with children using CSII, 
and support of the care giver.  This enables to child to continue using CSII, but can be flexible 
based on the needs of the child.  The outer two circles of the Neuman’s System Model include 
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the normal line of defense and the flexible line of defense.  The flexible lines of defense are able 
to adjust with the environment.  The flexible lines change with the need of the child as in the 
case of hyperglycemia.  Hyperglycemia can be related to poor eating habits.  Encouraging proper 
eating habits can aid in improving hyperglycemia.  The stability of the basic structure is 
dependent on all other factors, whether the factors are internal or external and the ability of the 
structure to adapt.  This is especially true with diabetic children who have a supportive center 
which possess the ability to give and take.  This ultimately improves the child’s overall well-
being (Alligood, 2010). 
Chapter 2:  Literature Review 
Eligibility.  Eligibility for articles included in this literature review consisted of several 
different criteria.  Two main criteria that needed to be present were:  the use of CSII in 
comparison to MDI and had to include children 18 years old or younger as part of the study.  
Other criteria that needed to be present were reported HbA1c levels with CSII use versus MDI 
use and hypo-and hyperglycemia episodes with CSII use.  Articles that were published before the 
year 2000, included adults only, or did not examine pertinent data previously mentioned above 
were excluded.  Length of study was not a determining factor whether or not to include the 
article.   
Information Sources.  Articles were retrieved from multiple sites.  Using the EBSCO 
research database accessed via Southern Adventist University website, several articles were 
obtained.  Other articles were retrieved from the Diabetes Care and American Academy of 
Pediatrics on-line archives from previous publications.  Ovid Nursing and the National Institute 
of Health on-line were also used for article reviews.   
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Search.  When searching for articles on-line, the search was limited to articles from 2001 
to 2012.  Criteria that was used to find articles foremost was CSII in children.  Other information 
used was CSII versus MDI and children, insulin therapy in children, and hypoglycemia in 
children.   
Study Selection.  Articles that were included in the review of literature based on either 
the use of CSII or the comparison of CSII with MDI therapy.  Hb1Acs were reported comparing 
CSII versus MDI use.  One article that was included in the review, examined adults and children, 
but since the article met the other criteria it was included.  If articles did not examine the effects 
of CSII on hypoglycemia, hyperglycemia/DKA and/or QOL, the articles were rejected.  Some 
articles specifically examined the use of CSII in adults.  Other articles only reviewed clinical 
trials using CSII, which were not included.  
Chapter 3:  Discussion 
 The articles that were chosen were reviewed and information was gathered to examine 
the PICOT question.  Findings concerning HbA1c, hypoglycemia, hyperglycemia/DKA, and 
overall effect on the child’s QOL were included in this discussion.  All of the findings are 
summarized in Appendix A. 
HbA1c findings.  Nuboer et al. (2008) examined HbA1c in children, ages four to 16, 
over a 14 month time frame who used CSII versus MDI therapy.  A run-in-phase of three and 
one-half months was used at the beginning of the study for all participants.  This phase consisted 
of the individual using three short-acting insulin injections before meals and one injection of 
intermediate-acting insulin at bedtime.  After completing the run-in-phase individuals were 
separated into either into group A using CSII therapy or group B using MDI therapy.  Diabetes 
education, constant glucose monitoring, and nutritional advice were given to individuals 
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throughout the length of the study.  The initial HbA1c for the MDI group was 8.40 ± 1.06% and 
at the completion of the study 7.98 ± 0.57%.  The CSII group had an initial HbA1c of 8.26 ± 
0.80% and at the completion of the study 7.66 ± 0.56%.  Although the results did not have a 
significant P value, some improvement in lower HbA1c was noted in both groups.   
Müller-Godeffroy et al. (2009) studied diabetic children, eight to 16 years of age, from 18 
different diabetic treatment centers to compare the effects of switching the participants from 
MDI therapy, which was not described in the study, to CSII therapy and if any improvement 
would be noted in the QOL and HbA1c.  During the transition from MDI to CSII therapy, the 
participants were hospitalized from three to seven days for CSII adjustments.  The mean HbA1c 
in the 12-16 age-group at the start of the study was 8.0 ± 1.56% which was significant with P < 
0.05 when compared to the mean HbA1c 7.6 ± 1.33% at the end of the study.  The other two age 
groups four to seven and eight to 11 did show improvements, but the improvements were not 
significant.   
Nabhan et al. (2008) compared glycemic control in toddlers and young children, under 
the age of five.  The participants were initially divided into either the CSII or MDI group.  After 
six months the MDI group was transitioned to CSII therapy. The mean HBA1c was compared 
when compared to HbA1c at the end of the study and there was significant improvement with 
HbA1c at the start of the study 8.9 ± 0.6% versus 8.5 ± 0.7% at the end of the study, with P= 
0.006.  Nabhan also found that the parents whose children used CSII therapy had significantly 
lower stress with P < 0.02. 
Sulmont et al. (2010) found improvement in HbA1c in children less than six years of age 
over eight years.  A cohort design was used to assess whether or not the use of CSII would 
improve HbA1c and glycemic control long term in children.  There were 66 participants, 34 of 
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which continued on their current MDI therapy and the other 32 participants were started on CSII 
therapy at the time of diagnosis.  During the study, the mean reduction in HbA1c in the CSII 
group reached statistical significance during year four with P = 0.015, year five with P = 0.010, 
and year seven with P = 0.025.   
 Berhe et al. (2006) evaluated the glycemic control, safety and efficacy of continuous 
subcutaneous insulin infusion with pump therapy in two to seven year olds.  The participants 
were initially on MDI therapy, with at least two injections per day of short-acting insulin and 
intermediate-acting insulin, for at least one year prior to the study.  At the start of the study the 
participants were transitioned to MDI therapy and continued on the same short-acting insulin. 
Data was obtained at least one year prior to the study and one year after the study.  Berhe found 
that before the implementation of the CSII therapy, 65 percent of the children had a HbA1c 
greater than 8.5% and after the study, 76 percent of children’s HbA1c was less than 8.5%.  Forty 
percent of the children in this study had a reduction of greater than 0.8% in HbA1c level, which 
was significant with P<.001.   
Nelson et al. (2009) examined the HbA1c values during the first 12 months after 
changing from MDI to CSII therapy in children nine to 18 years of age.  The ideal HbA1c of 
7.6% was used as a standard when comparing HbA1c.  One month prior to initiation of CSII 
therapy the participants’ HbA1c was measured and again at one, four, eight and 12 months.  The 
participants were divided into five groups.  Of the 30 participant’s ages nine to 18 years old, 
there were 18 females and 12 males.  Group one consisted of five school-age children and three 
adolescents and achieved the ideal HbA1c within one month of CSII therapy and able to sustain 
the level over 12 months.  Group two achieved the ideal HbA1c at the initiation of CSII, but 
failed to maintain this at the eight and 12 month HbA1c measurements.  Group three was not 
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able to meet the ideal HbA1c.  Group four’s HbA1c remained above 8% during the 12 months.  
The fifth group did not show any constituent trends in either increasing or decreasing HbA1c and 
all of the HbA1c’s obtained were above the ideal HbA1c.   Nelson felt that the HbA1c was not 
achieved by some of the participants because of excessive carbohydrate eating, skipping meals, 
or stress in the home causing a decrease in parental involvement. 
 Weintrob et al. (2003) used a randomized open cross over trial with MDI and CSII 
therapy.  Participants, ages eight to 14 years of age, were assigned either to the MDI or CSII 
group.  Participants remained in the groups for three and one-half months and were then 
transitioned to the opposite therapy.  Three months before the study began, participants, along 
with his or her family, were involved in educational sessions.  These sessions included strict 
glucose monitoring, carbohydrate counting, and insulin adjustments to prevent DKA.  The initial 
HbA1c three months prior to the study was 8.9 ± 1.0%.  At the end of the study the mean HbA1c 
was 8.0 ± 0.8%, which is statistically significant with P < .001.  However at the end of the study, 
the CSII HbA1c was 8.0 ± 0.7% and MDI HbA1c was 8.1 ± 0.8% with P = 0.03.  Weintrob 
stated that the most likely reason for no difference in HbA1c between the two groups was the 
educational sessions prior to the start of the study.      
 Edwards et al. (2011) examined the use of CSII to see if this would improve glycemic 
control in children within one month of the diagnosis of type I diabetes.  To be included in this 
study, participants, ages eight to 18 years of age, had to have a diagnosis of type I diabetes for 
less than four weeks.  The participants either continued using MDI therapy or were started on 
CSII therapy.  HbA1c measurements were taken at the onset of diagnosis, one, three, six, nine, 
and 12 months.  The CSII group showed lower HbA1c values during the first six month interval 
of the study, but did not maintain this at the 12 month interval.  
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 Doyle et al. (2004) studied whether or not CSII therapy would improve HbA1c in 
participants, ages eight to 21 years of age, when compared to MDI therapy using short and long-
acting insulin, glargine.  At the beginning of the study the participants who used MDI therapy 
was 8.2 ± 1.1% and the CSII therapy participants HbA1c was 8.1 ± 1.2%.  At the end of 16 
weeks, those who used CSII therapy had improvement in HbA1c 7.2 ± 1.0% which was 
significantly lower compared to the MDI therapy HbA1c 8.1 ± 1.2%.  Comparing the mean 
baseline HbA1c P < 0.002 and when the HbA1c was compared between the two groups P < 
0.005.   
Fox et al. (2005) compared an MDI group, using two to three injections per day with 
rapid-acting and intermediate-acting insulin, with a CSII group for six months.  Participants were 
12 to 72 months of age.  Despite not having significant improvements in HbA1c between the two 
groups, it is noted that CSII group had slight improvement in the HbA1c with baseline HbA1c of 
CSII group 7.43 ± 0.48% and at the end of six months HbA1c 7.24 ± 0.31% with P = 0.58 when 
compared to the MDI group baseline HbA1c 7.57 ± 0.27% and at the end of six months 7.46 ± 
0.18% with P =0.60.   
 Weinzimer et al. (2004) examined the safety of using CSII in young children under the 
age of seven.  All of the participants in this study used CSII therapy.  At the end of the study, 
which was 30 months long, the mean HbA1c for all post-pump visits was 7.1 ± 0.8%.  The 
children older than three years of age seemed to have modest improvement in HbA1c, although 
not significant when compared to the children younger than three.  Weinzimer noted that 
although there were fewer hypoglycemic episodes and that CSII in young children appears to be 
safe, the physician’s evaluation of the child and caregiver should mandate when CSII therapy is 
initiated.   
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McMahon et al. (2004) examined the impact of CSII in children and adolescents, who 
previously had elevated HbA1c, which was not defined in the study, and recurrent hypoglycemic 
episodes.  HbA1c levels were recorded at the start of CSII therapy and then every three months 
for a total of 24 months.  Prior to initiating pump therapy the HbA1c was 8.3 ± 0.1% and after 
initiation of CSII therapy the HbA1c was 7.8 ± 0.1% with P < 0.001. 
Wood et al. (2006) examined from 1998 to 2001 why some youth, from the ages of 11 to 
17, chose to continue CSII therapy and why others chose MDI therapy.  Wood found that the 
ones who chose MDI over CSII therapy were less adherent to monitoring glucose, eating healthy, 
and exercising.  The youth who continued to use CSII therapy after one year had improvement in 
the HbA1c.  Wood found that individuals, using CSII therapy, who monitored glucose levels 
frequently had a greater improvement in HbA1c.  At the end of the study the HbA1c levels using 
the CSII therapy was 8.4 ± 1.2 % when compared to those who discontinued CSII therapy and 
chose to use MDI therapy the HbA1c was 9.4 ± 2% with P = 0.01.   
Burdick et al. (2004) examined the effect of CSII on HbA1c, but more specifically those 
children, less than 18 years of age, who already had CSII, greater than six months, and reasons 
for less than optimal control.  Thirty-five percent of the individuals missed less than one meal 
bolus per day had a HbA1c of 8% compared to  65 percent of individuals who missed more than 
one meal bolus per day had a significantly increased HbA1c of 8.8% with P = 0.0001.  Burdick 
pointed out that to continue to have optimal control with CSII, the child or adolescent must 
continue to give meal boluses in the same nature he or she would give an injection of insulin, as 
in the case of MDI.   
 Nirmi et al. (2006) examined individuals younger than 40 years of age, who had used 
MDI therapy for at least one year prior to using CSII therapy.  Participants were divided into 
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three different groups; the pre-pubertal, adolescent, and young adult.   HbA1c levels were 
collected when the individuals were using MDI therapy and during the time the individuals were 
using CSII therapy.  Nimri found that the mean HbA1c levels were lower during the time of CSII 
therapy than during the MDI therapy with an average reduction of HbA1c by 0.51% with a P < 
.001.  The HbA1c during the time of MDI therapy was 8.5 ± 1.5% and the last HbA1c 
measurement on CSII therapy was 7.8 ± 1.3%. 
Raccah et al. (2009) examined the use of a continuous glucose sensor in diabetic patients 
with a HbA1c greater than 8% at the start of the study to see if there was any improvement in 
using CSII therapy with the sensor compared to CSII without using the sensor.  The study 
included adults and children with 51 of the 132 participants being children.  Those in the CSII 
sensor group had significantly lower HbA1c levels than the CSII non-sensor group with HbA1c 
levels.    
Plotnick et al. (2003) examined children and adolescents, ages four to 18 years of age, in 
a trial for 28 months with CSII and MDI therapy.  HbA1c levels were collected for six to 12 
months prior to the study and every three months after the study began.  During the three to six 
months the children and adolescents with CSII therapy had HbA1c levels that were significantly 
improved when compared to the start of CSII.  When reviewing the HbA1c at the six month 
mark there was a notable trend of increasing HbA1c.  This rise in HbA1c was thought to be 
related to either age or the length of time that the child or adolescent had type I diabetes.   
Hypoglycemia.  Nuboer et al. (2008) also found a decrease in severe hypoglycemic 
events (average of 0.29 episodes), which indicates a threefold reduction of severe hypoglycemic 
events that occurred in the CSII group.  Sulmont et al. (2010), when comparing CSII to MDI 
groups, noted fewer episode of hypoglycemia with P = .016.  In the Weinzimer et al. (2008) 
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study the rates of hypoglycemic episodes were similar between the two groups.  However, it was 
noted more hypoglycemic episodes occurred during the day rather than at night which is 
consistent with more activity.  The risk of hypoglycemia at night related to CSII use continues to 
be a concern for many physicians and practitioners, but this study found that hypoglycemia was 
more common during the day.  Wilson et al. (2005) noted that one CSII participant and one MDI 
participant suffered severe hypoglycemic episode, but the CSII participant also had similar 
episodes while using MDI prior to the study. 
 The non-randomized trial by Weinzimer et al. (2004) found significant improvement in 
hypoglycemia.  In the study, severe hypoglycemia rates decreased as a whole by 53%, from 78 
events per 100 patient-years to 37% per 100 patient-years with P = .02.  The greatest 
improvement noted was in the severe hypoglycemia events occurring in children three to five 
years of age, whose rates decreased by 79%, from 141 to 29 events per 100 patient-years P < 
.001.  Weinzimer pointed out that using CSII in younger children is safe and effective and should 
be considered as a treatment plan.   
 The retrospective study by Nimri et al. (2006) also showed improvement in 
hypoglycemia.  There were no episodes of severe hypoglycemia in the pre-pubertal group, but in 
the adolescent and young adult groups, the number of severe hypoglycemic episodes per 100 
patient-years decreased significantly from baseline to one year after initiation of CSII therapy 
with P < .01 and P < .05, respectively.  Berhe et al. (2006) also noted significant decrease in 
hypoglycemia for children who used CSII with a P < .001.  Plotnick et al. (2003) examined the 
events of hypoglycemia prior to CSII therapy and with CSII therapy.  Plotnick found there were 
14.3 events per 1,000 patients versus 6.6 per 1,000 patients.   
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Hyperglycemia/DKA.  Nuboer et al. (2008) also found that with CSII therapy there were 
only two episodes of DKA when compared to the MDI group of four episodes.  Edwards et al. 
(2011) found that amount of time spent in hyperglycemia was decreased 21% in the CSII group 
compared to 36% in the MDI group with a P= 0.04.  When Weinzimer et al. (2007) compared 
aspart insulin versus lispro insulin it was noted that the rate of hyperglycemia was decreased by 
11% in the aspart group and 17 % in the lispro group.  Even though CSII was not compared to 
MDI, the results still indicate a decrease in hyperglycemia episodes.  In 2006 Nimri divided 
children and adolescents into groups by age and found the DKA of the pre-pubertal age group 
with a P = .057 was related to pump technicality.  The other two age groups, however, did not 
have any DKA episodes.  Wilson et al. (2005) found when comparing the hyperglycemia rates 
between CSII and MDI therapy, there was no difference noted between the two groups.  
Quality of Life.  Hilliard et al. (2009) found that youth had more issues with anxiety and 
depression prior to starting CSII therapy.  At the end of the study the youth had more improved 
QOL, improvement in depression and anxiety compared to the youth who used MDI therapy.  It 
was also found that children, with two or more adults in the home, had a more improved QOL 
than children with only one parent which was obtained from the Parent Report Questionnaire. 
 Müller-Godeffroy et al. (2009) examined if CSII would provide flexibility in lifestyle and 
affected family burden.  The Overall Diabetes Burden for parents with younger children reported 
less of a burden for themselves when the child used CSII.  Parents of school-aged children and 
adolescents also reported less stress for themselves.  Weintrob et al. (2003) found that 
participants of the study were more satisfied with CSII therapy rather than MDI therapy.  Wilson 
et al. (2005) found improvement in the QOL prior to CSII therapy and after completion of the 
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study for those participants in the CSII group, but when compared to the MDI group there was 
no significant difference.   
 Fox et al. (2005) examined the burden of disease between the mothers of the CSII and 
MDI group.  Fox found that the mothers of the MDI group felt more of an impact on life from 
the diabetes.  Fathers were also examined and it was found that those fathers of the MDI group 
felt more psychological distress than those fathers who children used CSII.  However, McMahon 
et al. (2004) did not see any improvement in the QOL of either the participant or the care giver.  
However, participants did report increased self-efficacy scores with CSII therapy.   
Limitations.  There were several limitations noted throughout this literature review.  The 
most notable limitation is the small sample sizes that were studied.  Partly, this is related to the 
fact the studies involved children.  Other limitations noted in some of the studies was the length 
of time - one study was only 16 weeks long.  Not all of the studies examined the same 
parameters as described in the PICOT question.  There were also fewer articles dealing with CSII 
therapy including children over the last two to three years, therefore a majority of the data is 
included from 2002 till present.  Very few magazines are targeted towards CSII therapy and 
therefore many articles came from Diabetes Care.  Insurance companies can also be a limitation 
in this study because of the cost of CSII therapy, which is very expensive, versus what the 
insurance company will pay and provide for the patient.  Also, retrieving some articles from on-
line sources required payment for articles being used and because of this, it excluded some 
articles from being used.   
Chapter 4:  Conclusions 
By examining all of the articles, specifically targeting Hb1c levels, hypoglycemia, 
hyperglycemia/DKA, and QOL certain conclusions can be made.  HbA1c, according to the 
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majority of the literature reviewed, improves with CSII therapy when compared to MDI therapy.  
Yet, it was noted that the CSII therapy improved significantly when the child and/or caregiver 
was educated and contacted by medical professionals often.  This supports the theory by 
Neumann that the system shifts with the environment, but with strengthening of the lines of 
defense the core becomes stronger.  No specific age group improved more with CSII therapy 
with regard to HbA1c than another group.  Each study had different age groups that did better 
than the other, but at this time it cannot be predicted that the age of the child or adolescent 
guarantees better glycemic control over other ages.   
When evaluating hypoglycemia and hyperglycemia/DKA, the episodes and the 
percentages of these events are decreased with CSII therapy.  Only a small percent of the studies 
showed no difference between the two groups.  This also could be linked with the fact that 
education was received about nutrition and checking glucose levels often throughout the day and 
night hours.  It was noted by several articles that increased amounts of glucose checks decreased 
the risk of these events.  Some of the studies did show some improvements in the QOL of either 
the child or the caregiver.  Although several studies commented that a majority of the 
participants wanted to continue on CSII therapy after the study was completed rather than MDI 
therapy.   
It was noted in several of the studies that children and adolescents required less insulin 
with CSII therapy when compared to MDI therapy.  Also, the BMI decreased with the use of 
CSII, which has been postulated by many to actually increase with CSII use.  The ultimate goal 
of CSII therapy is to provide strict glycemic control while providing flexibility and normalcy to 
the child and adolescent.  The PICOT question that was asked at the beginning of this literature 
review can be supported by the evidence provided in the articles presented.  One main 
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requirement to be able to meet this improved glycemic control is constant support and education.  
Without control, improved glycemic control cannot be achieved.   
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HbA1c with MDI use at start and 
end of study:  8.40 ± 1.06 compared 
to 7.98 ± 0.57.
HbA1c with CSII use at start and end 
of study:  8.26 ± 0.80  compared to 
7.66 ± 0.56
No significant improvement in 
Pediatric Quality of Life (p < 0.05).  
In CSII group, severe hypoglycemic 
episodes decreased an average of 0.29 
percent indicating a threefold 
reduction.  MDII = 4 episodes of 
DKA compared with CSII with only 
two episodes.
Mean HBA1c= 8.9 ± 0.06%.  
ANOVA showed significant changes 
in HbA1c over time (p= 0.007).
No difference between CSII and IIT 
(p=0.518) or interaction between 
time and group (p=0.454).  HbA1c 
compared with the baseline mean 
decreased significantly over the 
yearlong study in both groups (8.9 ± 
0.6 versus 8.5 ± 0.7%, p= 0.006).
HbA1c levels in group B (CSII) were 
lower than Group A (MDI) during 
the eight year follow up.  During year 
1 HbA1c in group B < 6.5%, P= 
.046.   The HbA1c compared 
between the two groups was 
statically significant at 4 years with 
P= .015.
Group B had fewer hypoglycemic 
episodes than Group A (P = .016).  
No difference in DKA between the 
two groups.
Nabhan et al., 
2008 
Cohort study
N= 66 children 
Group A( MDI therapy) = 34
Group B ( CSII therapy) = 16
Assess the long-term metabolic outcomes 
in children who were diagnosed with 
diabetes less than six years of age.
Randomized, 
prospective parallel 
design.
N =  38
Group A = 19
Group B = 19
Examining the changes in the QOL and the 
impact of the disease in CSII vs. MDI use 
in children
Nuboer et al., 
2008
Randomized 
Prospective Study 
with mixed method 
design
N = 35
Age =  3.7 ±  0.7
Males =  17
Females = 18
Duration of diabetes = 1.6  ±   0.6
Hemoglobin A1c (HbA1c)= 8.8  ±   
0.6
Body mass index (BMI) = 79.4  ±   
17
Compare diabetes control, neurocognitive 
functioning, and behavioral/family 
functioning in toddlers and young children 
treated with CSII therapy versus intensive 
insulin injection therapy (IIT).
Sulmont et al., 
2010
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HbA1c before (65% of the children 
was >8.5%) and after (76% of 
children was <8.5%).  40% of the 
children had a reduction of >0.8% in 
HbA1c level.  P<.001.
Hypoglycemia significantly reduced 
with a P < .001.  Also no reported 
seizures with CSII.
Group 1 : 5 school-aged children and 
3 adolescents achieved HbA1c of 
7.6% within 1 month of CSII therapy 
and sustained the level over 12 
months.  Prior to the study 4 of the 8 
had a HbA1c of 7.6% or less.  
Group 2:  5 school-aged children and 
4 adolescents.  Three of the 
individuals already had HbA1c less 
than the target goal.  The other 6 
individuals actually had a HbA1c 
above the target goal.
Group 3:  1 school-aged female and 1 
adolescent female.  The school-aged 
met the HbA1c requirement, but the 
adolescent did not.
Group 4:  Showed minimal change in 
HbA1c but was 8%.
Group 5:  No patterns noted in 
HbA1c and were all above the target 
HbA1c goal.
The rates of hypoglycemic episodes 
were similar between the two groups.  
More hypoglycemic episodes 
occurred during the day rather than at 
night which is consistent with more 
activity.
In both groups the incidence of 
hyperglycemia was lower (aspart 
11% and lispro 17%).
Nelson et al., 2009
Berhe et al., 2006
A repeated measures 
design guided study.
N= 30
Males= 12
Females=18
Examine the HbA1c values during the first 
12 months of CSII in children 9-18 years 
of age.
Evaluate the glycemic control, safety, and 
efficacy in CSII in children 2-7 years old
N= 33 Retrospective Study
16 week, open label, 
multicenter parallel-
group.
N=298 children and 
adolescents
Aspart N= 198
Lispro N= 100
Examine whether it is safe to use lispro or 
aspart insulin in CSII in children and 
adolescents.
Weinzimer et 
al., 2007
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HbA1c was significantly lower from 
the start of the study to the first 3 
month interval with HbA1c 8.9 ± 
1.0% vs. 8.0 ± 0.8%.  This change is 
thought to be related to increased 
glucose monitoring and education 
session prior to the study.
QOL:
The Diabetes Treatment Satisfaction 
Questionnaire (DTSQ) and the 
Diabetes Quality of Life 
Questionnaire for Youth (DQOLY) 
were used at the beginning and and at 
the end of each treatment arm of the 
study.  DTSQ satisfaction scale at 
beginning of study was 71.9 ± 14.5 
and was 74.8 ± 13.5 at the end of the 
study.  Overall scores of DTSQ at 
beginnning of MDI arm, 21.9 ± 3.8 
and at the end of the CSII arm 30.6 ± 
3.7, (P< .001).  No difference noted 
in the DQOLY with satisfaction scale 
71.9 ± 14.5 at beginnning of study 
and 73.5 ± 14.0 at the end of the 
study.
HbA1c in the CSII group were lower 
are 6 months, but did not maintain 
this at the 12 month interval.
Hyperglycemia episodes were 
decreased in the CSII group (21% vs. 
36%) P= 0.04
Prospective 
randomized pilot 
trial
N=24
Examine if starting CSII at the time of 
onset of diabetes preserved C-peptide 
secretion and had an improvement in 
glycemic control.
Edwards et al., 
2011
A randomized 
crossover design
N= 23 children (10 males)
Ages 9.4 to 13.9 years with type 
1 diabetes.
Compare the efficacy and feasibility of 
CSII with MDI in children with type 1 
diabetes.
Weintrob et al., 
2003
HbA1c values were similar between 
CSII and current therapy groups at 
baseline (7.43 ± 0.48 vs. 7.57 ± 0.27, 
CSII vs. current therapy, at 3 months 
(7.20 ± 0.29 vs. 7.46 ± 0.22), and at 6 
months (7.24 ± 0.31 vs. 7.46 ± 0.18).
QOL:
The pediatric Diabetes Quality of 
Life Scale, which was designed for 
this study was used examine how the 
child's diabetes effected the parent(s) 
interaction with the child or the childs 
behavior.  QOL was examined prior 
to the study and again at 6 months.
Fox et al., 2005
Assess the effects of insulin pump 
therapy on diabetes control and family 
life in children 1–6 years old with type 
1 diabetes.
N = 23
Males = 13
Females = 10
Randomized control 
trial.
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Post pump HbA1c:  7.8 (± 0.1)%. 
(Range 6.1–10.4%) (P < 0.0001)
Ages < 12 HbA1c pre-pump vs. post 
pump:  8.3 ± 0.2% vs. 7.5 ± 0.1% (P 
< 0.001).
Ages < 12 H bA1c pre-pump vs. 
post pump:   8.4 ± 0.1% vs. 7.9 ± 
0.1%.
Pre pump severe hypoglycemia 
(events/100 patient years): for < 12 
years = 25.9 and > 12 years = 37.5.
Post pump severe hypoglycaemia for 
(events/100 patient years):  < 12 
years = 8.3 and > 12 years = 13.5.
Modified version of the Diabetes 
Quality of Life Instrument (DQOL) 
was used (not defined in the study).  
43 questionnaires were gathered.  It 
was found the QOL prior to insulin 
pump therapy was 63.5 ± 2.1 and 
after the study was 68.6 ± 2.1.
Mean HbA1c:
Significantly lower during CSII 
therapy than during MDI therapy 
(−0.51%; P < .001) for the entire 
cohort.
Prepubertal (−0.48%; P < .05); 
Adolescent (−0.26%; P < .05); Young 
Adult (−0.76%; P < .001) groups
No episodes of severe hypoglycemia 
in the prepubertal group.  Adolescent 
and young adult groups, the number 
of severe hypoglycemic episodes (per 
100 patient-years) decreased 
significantly from baseline to 1 year 
after initiation of CSII therapy (P < 
.01 and P < .05, respectively).
Raccah et al., 
2009
Whether CSII will show improved 
metabolic control and evaluate change in 
glycemic variability.
N = 132
Children = 51
Adults = 81
Not described
HbA1c were significantly lower 
during CSII therapy than during MDI 
therapy (−0.51%; P < .001) for the 
entire cohort.
     Pre-pubertal (−0.48%; P < .05)
     Adolescent (−0.26%; P < .05)
     Young Adult (−0.76%; P < .001) 
groups
Design of study not 
mentioned.
N= 100
M = 41
F = 59
Age < 12 = 40
Age > 12 = 60
Determine the impact of insulin pump 
therapy on key parameters of diabetes 
management including quality of life in 
children and adolescents with Type 1 
diabetes mellitus (T1DM).
McMahon et al., 
2004
Retrospective paired 
study longitudinal 
analysis.
N= 279  
Prepubertal= 23 with age range 
1.6–8.6 years.
Adolescents= 127 with age 
ranges 9-17 years.
Young adult = 129 with ages 
ranges 17-40 years.
Compare by age and glycemic control 
continuous subcutaneous insulin infusion 
with multiple daily injections in youth 
with type 1 diabetes.
Nimri et al., 2006
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HbA1c was signinicantly improved 
after CSII therapy was started (P = 
0.03).  At 6 months trend noted in 
HbA1c to be increasing with (P < 
0.001).  
Hypoglcemic events decreased after 
CSII therapy started.  14.3 per 1,000 
patient months prior to CSII and 6.6 
per 1,000 patient months after CSII.
One episode of DKA prior to CSII 
and one episode during CSII.
Burdick et al., 
2004
Identify causes of poor glycemic control 
in youths who use CSII therapy
N = 48
F = 23
M = 25
Not described
HbA1c in the 13 to 15 year old age 
group had highest HbA1c  of 8.8 % 
and highest number of missed meal 
boluses.  Children < 13 had best 
HbA1c of 8.4%.  
Wood et al., 2006
Examine reasons for CSII discontinuation 
and predictors of insulin pump success.
N = 161 Not described
HbA1c baseline prior to CSII therapy 
was 8.4 ± 1.4 and after 1 year of 
CSII  therapy was  8.0 ± 1.3.  Those 
who discontinued CSII therapy 
had HbA1c at basel ine prior to 
trying CSII was  8.5 ± 1.4 and after 
discontinuation 8.6 ± 1.3.
Not described
N =95
F = 52
M = 43
Evaluate safety and effectiveness of CSII 
therapy in children and adolescents with 
type I diabetes.
Plotnick et al., 
2003
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HbA1c range in 4-7 age-groups prior to study 
and after:  3.7 to 10.1 compared to 4.7-9.4.
HbA1c range in 8-11 age-groups prior to study 
and after:  7.6 ± 0.78% compared to 7.4 ± 0.85%.
HbA1c range in 12-16 age-groups prior to study 
and after:  8.0 ± 1.56% compared to 7.6 ± 1.33%. 
Significant with P < 0.05.
No significant decrease in severe hypoglycemia.
KINDL_DM: Scores increased significantly in 
medium effect size adolescents and large effect 
size in school-ages children and younger children.
PIP: Decrease in some of the subscales, but did 
not meet previously defined significance level of 
P < 0.005.
HFS-P Worry scale: Significant decrease in 
hypoglycemia –related worries.  Effect size 
moderate to large.
HFS-P Behavior Scale: No decrease in this scale 
and less frequency of feeding behavior problems.  
Effect size moderate to large.
Overall Diabetes Burden: Parents of younger 
children reported significantly less burden for 
themselves.
Mean t0=3.62 ± 1.06, mean t1 = 3.12 ± 1.1) and 
to the child with diabetes (mean t0 = 3.00 ± 1.12, 
man t1 = 2.36 ± 0.76.
Difference statistically significant with ( Z = -
3.23, -4.15, P< 0.01, Wilcoxon test, two-tailed 
testing), with moderate to large effect size (d= 
0.5 – 0.8).
Parents of school-age children  and adolescents 
reported significant less Overall Diabetes Burden 
in regard to themselves (8-11 years: mean t0 3.54 
±0.92, mean t1= 2.64 ± 0.87, Z= -3.57, P < 
0.001; 12-16 years:  mean t0 = 2.70 ± 1.01, mean 
t1 = 2.40 ± 0.82, Z= -2.36, P < 0.05) 
Child with diabetes 8-11 years  mean t0= 3.50 ± 
0.95, mean t1 = 2.54 ± 1.03, Z= -3.24, P< 0.01
12-16 years:  mean t0= 3.07 ± 1.02, mean t1 = 
2.64 ± 1.01, Z= -3.05, P <0.01).
Effect size large in school-aged children and 
moderate in adolescents.
Müller-Godeffroy et 
al., 2009
Investigate different 
psychosocial features 
which might be relevant 
for patients and parents 
using CSII therapy
N = 117
Males - 64
Females - 53
Child age 10.5 ±3.7 years
8-11 years-25
12-16 years- 63
Parents of 4-7 year olds- 29
See table 1 pg. 495
Pilot Study
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Significantly decreased HbA1c from 
8.34 to 7.82 ( -.052%, p= 0.001).  
Within-patient analysis showed a 
decreased HbA1c at the end of the 7-
10.5 month CSII period by 0.22% 
(p=0.02) while using an average of 
0.27U/kg/d less insulin, p< 0.001.  
Children with HbA1c levels >8% at 
the start of CSII  (means 9.1  ± 1.0) 
showed a decrease in HbA1c to a 
mean of 8.56  ± 1.0 after 7 -10.5 
months of CSII 9 p=0.001).
QOL:
The Diabetes Quality of Life for 
Youth Scale (DQOL-Y) is a 53 -item 
questionnaire that was used to 
examine how diabetes impacted the 
individuals life, concern about having 
diabetes, and satisfaction with life.  
The QOL improved most in children, 
who had more anxiety, depression, 
longer illness duration, and had at 
least two adult caregivers in the 
home.  
Baseline HbA1c: Mean HbA1c 
was 8.0% ± 0.8.
HbA1c post study: There was no 
significant difference (P = 0.44, 
Student’s t test) in the change in 
HbA1c between the two groups 
(−0.21 ± 0.67%, CSII; 0.04 ± 0.71%, 
MDI).
None of the participants 
developed DKA
One CSII and one MDI participants 
suffered severe hypoglycemic 
episode, but the CSII participant also 
had similar episodes while using MDI 
prior to study.
HbA1c levels at baseline:
Similar in the glargine and CSII 
groups (8.2 ± 1.1 vs. 8.1 ± 1.2%, 
respectively, P = 0.89).  After 16 
weeks of glargine treatment, HbA1c 
levels (8.1 ± 1.2%) were not 
significantly different from baseline.
HbA1c levels fell sharply in the CSII 
group to 7.2 ± 1.0 at 16 weeks (P < 
0.02 vs. baseline and P < 0.05 vs. 
glargine group).
Randomized 1-year 
feasibility trial
N= 19 subjects
CSII group = 9
MDI group = 10
Prospectively conduct a 1-year, 
randomized, controlled, open-label 
feasibility trial comparing CSII with MDI 
in young children with diabetes.
Wilson et al., 
2005
Compare the efficacy of CSII to MDI 
with glargine in lowering HbA1c levels in 
children and adolescents with type 1 
diabetes.
Doyle et al., 2004 N=32
Randomized, 
prospective trial
Open parallel, 
randomized controlled 
perspective 
comparative study
N=77
4-7 years old: 9
8-12 years old: 7
13-16 years old: 7
Males: 17
Females: 21
Investigate the changes in quality of life 
and of impact of disease by either CSII or 
MDII 
Hilliard et al., 
2009
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QOL:
The pediatric Diabetes Quality of 
Life Scale, which was designed for 
this study was used examine how the 
child's diabetes effected the parent(s) 
interaction with the child or the childs 
behavior.  QOL was examined prior 
to the study and again at 6 months.
Mean HbA1c fell from 7.4 ± 1.0% in 
the year before pump initiation to 7.0 
± 0.9% at 12 months after pump 
initiation (P < .001).
Glycemic control improved during 
the follow up period; mean HbA1c of 
6.8 ± 0.6% at 3 years of follow-up (P 
= .003 from prepump values) and 6.5 
± 0.9% in the 6 children who amassed 
4 years of follow-up. The mean 
HbA1c for all postpump visits was 
7.1 ± 0.8%, and the mean for each 
subject's most recent visit at the time 
of data closeout (at a mean duration 
of follow-up of 30 months) was 7.0 ± 
0.9% (P < .02 from prepump values).
HbA1c levels were most notable in 
children < 3 years old, who had a 
prepump value of 7.9 ± 1.1% to a 
mean postpump value of 6.9 ± 0.9% 
(P = .01). “Older” children 
experienced a more modest 
improvement, from 7.4 ± 0.9% to 7.2 
± 0.6% in the 3 to <5 years group, 
and from 7.2 ± 0.9 to 7.1 ± 0.9% in 
the 5 to < 7 years group, neither of 
which reached statistical significance.
SH (severe hypoglycemia) rates 
decreased in the group as a whole by 
53%, from 78 events per 100 patient-
years to 37 per 100 patient-years (P 
= .02). The greatest improvement in 
SH occurred in the children 3 to < 5 
years of age, whose rates decreased 
by 79%, from 141 to 29 events per 
100 patient-years (P < .001).
DKA:  postpump period was 4 
episodes per 100 patient-years.
Weinzimer 2004
Analyze the CSII efficacy and safety data 
in very young children with type 1 
diabetes from our Diabetes Clinic 
database.
N= 65
Gender, F/M= 38/37
< 3 years= 11
3-< 5 years = 26
5- < 7 years = 28
Non-randomized 
uncontrolled design.
